Targeting Bladder Cancer with Inactivated Uropathogenic <i>E. coli</i>: A Novel Alternative to BCG Immunotherapy.

In contrast, higher doses (10 8 ) resulted in a marked survival advantage, reaching statistical significance and showing a strong trend for 10 9 –10 10 CFU equivalent ( Figure 7 B).

also in 5,725 other papers